Produção Nacional
Revisado por pares
Clinical nephrology - IgA nephropathy, lupus nephritis, vasculitis
2013; Oxford University Press; Volume: 28; Issue: suppl 1 Linguagem: Inglês
10.1093/ndt/gft113
ISSN1460-2385
AutoresJun Wu, Shiwei Duan, Wenbin Li, Ying Wang, W. Liu, Jian Zhang, L. Lun, X. Li, Han Chen, Y. H. Zheng, S. Liu, Yuanyuan Xie, Guoxiang Cai, X. Chen, P. Shen, Y. Li, Z. Wang, W. Wang, Hong Ren, Wen Zhang, Nan Chen, M. Shimamoto, Isao Ohsawa, Hitoshi Suzuki, Shigeki Nagamachi, Y. Shimizu, S. Horikoshi, Yasuhiko Tomino, Sharon Natasha Cox, Grazia Serino, Fabio Sallustio, Francesco Pesce, F. P. Schena, Emilie Kalbacher, Michel Ducher, Denis Fouque, Barbara J. MacGregor, François Combarnous, Jean‐Pierre Fauvel, Cristina Sarcina, Franco Ferrario, Veronica Terraneo, Antonello Pani, G. B. Fogazzi, G. B. Visciano, Ilaria De Simone, Francesco Rastelli, Claudio Pozzi, Ihm Soo Kwak, Eun Young Seong, Harin Rhee, D. W. Lee, S. B. Lee, B. Y. Yang, Myung‐Jun Shin, I. Y. Kim, Μaria Stangou, C. Bantis, S. Kasimatis, Μ. Σκουλαροπούλου, G. Toulkeridis, A. Pantzaki, Aikaterini Papagianni, G. Efstratiadis, Koshi Yamada, Hiyori Suzuki, Yusuke Suzuki, Milan Raška, Huang Zq, Colin Reily, Zina Moldoveanu, Krzysztof Kiryluk, Bruce A. Julian, Yasuhiko Tomino, Ali G. Gharavi, Jan Novák, R. Camilla, R. Coppo, S. Bellur, D. Cattran, H. Terence Cook, J. Feehally, S. Troyanov, Ian Roberts, L. Vergano, L. Morando, M. Mizerska-Wasiak, J. Maldyk, Agnieszka Rybi–Szumińska, Piotr Adamczyk, Beata Bieniaś, Katarzyna Gadomska-Prokop, R. Grenda, Małgorzata Zajączkowska, Roman Stankiewicz, Anna Wasilewska, Maria Roszkowska–Blaim, Xuan Zhang, Jing Xie, W. Wang, Xiao-Xia Pan, Simin Guo, P. Shen, Wen Zhang, N. Chen, A. Soylu, Yeşim Öztürk, Y. Dogan, D. Ozmen, Osman Yılmaz, Salìh Kavukçu, Ji‐Young Choi, G.-y. Park, H. Y. Jung, K. H. Kim, Owen Kwon, J.-H. Cho, C.-D. Kim, Y.-L. Kim, So Hyun Park, F. Berthoux, Hesham Mohey, B. Laurent, C. Mariat, Yanxia Chen, Wen Zhang, Jing Xu, N. Chen, Dóra Bajcsi, A. Haris, G. Ábrahám, Péter Légrády, Kálmán Polner, Benedek Rónaszéki, Zsolt Balla, Zoltán Rakonczay, Béla Iványi, S. Sonkodi, P. H. Bredin, Mark Canney, Claire Kennedy, Luke Plant, Michael R. Clarkson, Noshaba Naz, Minoti Hiremath, Anindita Banerjee, Yatrik M. Shah, Claudia Yuste, Alina Casian, Cristina Jironda, D. Jayne, Ross C. Smith, Matthew R. Lewin, Rachael Jones, P. A. Merkel, D. Jayne, C. Izzo, Marco Quaglia, E. Radin, A. Airoldi, R. Fenoglio, E. Lazzarich, P. Stratta, V. L. Onusic, M. J. C. L. N. Araújo, L. C. Battaini, L. B. Jorge, C. B. Dias, Myrthes Toledo-Barros, R. Toledo-Barros, Viktória Woronik, C. L. Cirami, Pasquale Gallo, Ester Romoli, Federico Mecacci, Serena Simeone, E. E. Minetti, G. Mello, F. Rivera, A. Segarra, Manuel Praga, Marco Quaglia, E. Radin, C. Izzo, A. Airoldi, E. Lazzarich, R. Fenoglio, P. Stratta, C. B. Dias, J. Lee, Luzia Ilza Ferreira Jorge, D. Malheiro, R. T. Barros, Viktória Woronik, E. V. Zakharova, E. S. Stolyarevich, Arzu Velioğlu, Dilara Güler, S. Nalcaci, G. Birdal, Hakkı Arıkan, Mehmet Koç, Haner Di̇reskeneli̇, Serhan Tuğlular, Çeti̇n Özener, Maria Guedes Marques, Patrícia Cotovio, Francisco Ferrer, Carlos Eduardo da Silva, Carlos Augusto de Oliveira Botelho, Karina Lopes, Pedro Maia, A. Carreira, Michel Leandro de Campos, Sabah Mohamed Alharazy, Norella Kong, M. Mohammad, Shamsul Azhar Shah, Abdul Halim Abdul Gafor, Anthony R. Bain,
Tópico(s)Systemic Sclerosis and Related Diseases
ResumoIntroduction and Aims: To evaluate the efficacy and safety of telmisartan combined with clopidogrelin and/or leflunomide for patients with lgA nephropathy and whether the combination therapy surpass telmisartan in decreasing proteinuria and protecting renal function.Methods: We enrolled 400 patients aged 18-55 years from 13 centers in Beijing who had proteinuria 0.5˜3.5gper day, baseline serum creatinine (SCr) 0.05).After treatment for 24 weeks, a significant decline of proteinuria was observed in the four groups (P <0.05), while those in group C (1.20±0.76vs 0.77±0.42g/24h) and group D (1.16±0.63vs 0.74±0.49g/24h) were decreased more significantly than in group A (1.15±0.87vs 0.92±0.58g/24h) and group B (1.11±0.83vs 0.89±0.42g/24h) (P<0.05).Mixed effects were showed that telmisartan, leflunomide, and telmisartan combined with leflunomide were effective in lowering proteinuria (P<0.01) by model analysis.The extent of serum creatinine decline in group C and group D displayed more significantly than that in group A and group B (P<0.05).The levels of eGFR in group C and group D were increased more than those in group A and group B. The decline of serum uric acid in group C and group D displayed more significantly than group A and group B (P 0.05).No obvious adverse reactions were found in the four groups.Conclusions: In the selected patients with IgA nephropathy, telmisartan combined with leflunomide was safe and effective in decreasing proteinura and protecting short-term renal function.Larger randomized studies would be needed to confirm these results in the long run.
Referência(s)